ScripHuntington’s disease (HD) has been a notoriously difficult field for drug development but enthusiasm is growing, not least at Skyhawk Therapeutics which has initiated a Phase II/III trial on a potenti
Pink SheetEisai and Eli Lilly are to appeal against today’s final decision by England’s health technology assessment institute, NICE, to deny funding for their respective Alzheimer’s disease drugs – Leqembi and
ScripWelsh biotech Draig Therapeutics has come out of stealth backed by an impressive line-up of healthcare investors and led by a highly experienced leadership team as it bids to become a major player in
ScripSage Therapeutics appears to have finally secured a palatable exit for investors after facing R&D setbacks and cost cuts and rejecting an initial buyout offer from its Zurzuvae (zuranolone) commer